Stockreport

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Xenon Pharmaceuticals Inc. - Common Shares  (XENE) 
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.xenon-pharma.com
PDF Monthly reductions in seizure frequency of 90.9% among participants treated for =48 months in the OLE, with 38% achieving =1 year of seizure freedomNew X-TOLE OLE data a [Read more]